MHRA consults on reclassification of domperidone 10mg tablets (Motilium 10) from POM to P

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

NeLM news service

MHRA consults on reclassification of domperidone 10mg tablets (Motilium 10) from POM to P

Source: MHRA

Date published: 26/03/2009 15:30

Summary

by: Yuet Wan

The MHRA is consulting on the reclassification of domperidone 10mg tablets (Motilium 10) from POM to P for the additional indications of nausea and vomiting of less than 48 hours duration. Comments should be submitted by 7th May 2009.

About this library entry

Category: 4.6 Drugs used in nausea and vertigo | Medicines and Healthcare products Regulatory Agency (MHRA) | Nausea and vomiting | OTC medicines

NeLM area: News

Link

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.

Printer Friendly Version

Related evidence

4.6 Drugs used in nausea and vertigo

08/11/2011

SMC does not recommend aprepitant (Emend®) for the prevention of chemotherapy-induced nausea and vomiting

07/03/2011

SMC accepts fosaprepitant dimeglumine (IVEmend®) for prevention of nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy

08/02/2011

New CKS Topic: benign paroxysmal positional vertigo

Nausea and vomiting

08/11/2011

SMC does not recommend aprepitant (Emend®) for the prevention of chemotherapy-induced nausea and vomiting

07/03/2011

SMC accepts fosaprepitant dimeglumine (IVEmend®) for prevention of nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy

16/12/2010

Droperidol for treatment of nausea and vomiting in palliative care patients